Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 10/20 | 0.47 |
| ▸ | CDK8 | P49336 | 10/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 10/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3718468 | 0.87 | HTR2C (0.49) | RPS6KA3HTR2CCCNCCDK8CDK19 | |
| SCHEMBL3721532 | 0.85 | HTR2C (0.48) | RPS6KA3HTR2CCCNCCDK8CDK19 | |
| SCHEMBL3724774 | 0.82 | HTR2C (0.47) | RPS6KA3HTR2CCCNCCDK8CDK19 | |
| SCHEMBL3724527 | 0.82 | RPS6KA3 (0.53) | RPS6KA3CCNCCDK8CDK19 | |
| SCHEMBL27800359 | 0.77 | HTR7 (0.53) | HTR2CHTR7ROCK2HTR2BHTR6 | |
| SCHEMBL3723942 | 0.77 | ACVR1 (0.52) | HTR2CCCNCCDK8CDK19HTR7 | |
| SCHEMBL3721308 | 0.77 | HTR2C (0.55) | HTR2CROCK2HTR6ROCK1HRH4 | |
| SCHEMBL3720963 | 0.76 | JAK1 (0.55) | RPS6KA3 | |
| Hydrochloric Acid SCHEMBL3726557 | 0.76 | HTR2C (0.54) | HTR2CROCK2HTR6ROCK1HRH4 | |
| SCHEMBL3722854 | 0.75 | HTR2C (0.44) | RPS6KA3HTR2CCCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-101959887-B | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2013-07-31 | — | — | CN | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-101959887-A | Pyrrolopyridine as kinase inhibitor | ARRAY BIOPHARMA INC | 2011-01-26 | — | — | CN | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | RPS6KA3 450/4885HTR2C 4467/4885CCNC 246/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | RPS6KA3 455/4885HTR2C 4438/4885CCNC 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.